Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080369 | 1.00 | OPRD1 (0.71) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4577159 | 0.92 | CYP1A2 (0.73) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL5078483 | 0.92 | CYP1A2 (0.73) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4591150 | 0.92 | CYP1A2 (0.73) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL29457725 | 0.91 | OPRD1 (0.75) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL17158189 | 0.91 | OPRD1 (0.75) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL12018159 | 0.91 | OPRD1 (0.75) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL5143696 | 0.91 | OPRD1 (0.75) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4577164 | 0.91 | OPRD1 (0.75) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4577085 | 0.91 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125443-A1 | CARDIOPROTECTIVE DELTA OPIOID RECEPTOR AGONISTS AND METHODS OF USING SAME | ENTA HOLDING LLC | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125443-A1 | CARDIOPROTECTIVE DELTA OPIOID RECEPTOR AGONISTS AND METHODS OF USING SAME | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885CYP1A2 2152/4885CYP3A4 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.